More recently, Asciminib, an allosteric BCR::ABL1 antagonist specifically targeting the ABL1 Myristoyl Pocket (STAMP), has been demonstrated to have superior efficacy compared to Bosutinib and an improved safety profile in patients with CML-CP after at least 2 prior TKIs [6, 7]. This evidence concerns the gene BCR and chronic myelogenous leukemia, BCR-ABL1 positive.